After the vaccine storm, how to go the road of medical reform?

The "accountability storm" of Changchun Changsheng vaccine incident has swept across the country. The handling of relevant responsible persons from top to bottom involves a wide range and intensity, which is unprecedented. It is undoubtedly a "super typhoon" in the pharmaceutical industry. It also demonstrates the attitude and determination of the central government to the "four strictest" and "four have two responsibilities" in food and drug supervision. We have reason to believe that, this storm will also have a profound impact and positive significance on the future food and drug supervision!

The overwhelming comments on the Internet, the regrets about the leaving or staying of regulators, the review of the results of three years of pharmaceutical reform, the conjecture about the future direction of supervision, and the concerns about the continuity of policies ...... Different voices also reflect the confusion and perplexity of the entire pharmaceutical industry about the future ...... It is also inevitable that some concerns will arise:

Concern one:

A series of reform measures in the pharmaceutical industry in the past three years are obvious to all, and history will judge whether it is right or wrong. Of course, all the problems in the industry are "frozen in three feet", and it is by no means "a day's work" to completely solve them ". At the critical moment of the three-year reform, regulatory concepts and policies and regulations need to be implemented more, and they need to continue to strengthen their implementation. The road to pharmaceutical reform is full of difficulties and obstacles, and time is tight. Everyone hopes that the next regulatory team can continue to steadily advance. The pace of reform to ensure the continuity of policies and the seriousness of supervision......

Concern two:

There are two voices about the future of regulation, one is worried about such strict accountability, in the future, will there be negative laziness and inaction from the top to the bottom of the regulator... Only focus on superficial phenomena, not actively discover and solve deep-seated problems... Deliberately conceal problems... Report good news but not bad news... More than one thing is better than less... Even retreat in the face of difficulties... The second is that the regulator may strictly abide by the "dogmatism" and "one-size-fits-all" treatment, which does not allow pharmaceutical companies to overstep, enterprises are simply "kidnapped" by laws and regulations, lacking the power of process improvement and technological innovation......

Concern three:

State Administration of Market Supervision and Administration, State Drug Administration, provinces, cities, prefectures and counties... The rights, division of responsibilities and coordination of work in drug supervision, food and drug supervision, has always been a thankless errand, with large responsibilities and small rights, it is difficult to balance the interests of the whole process of the whole life cycle of "medicine" and "medicine"... To put it bluntly, "food and drug supervision" is a hot mountain, from the division, division and combination of the "five rounds" of system reform in the past 20 years, we can see the clue. Whether the future supervision direction is "strengthened" or "weakened" depends not only on the strength of "supervision" and "accountability", but also on the implementation of "power" and "responsibility" in "institutions" and "policies......

Concern four:

The professionalism of the drug supervision team and the technicality of drug supervision have always been the topic of "disease". However, under this "heavy pressure", in the past three years, everyone has worked overtime to issue regulations and documents every day, and even stood by 24 hours ...... It is conceivable that there will be a large number of drug supervision personnel "retreating" in the future. The professionalism of the drug supervision team needs to be improved and its stability needs to be strengthened, the industry needs "stronger supervision" and better opportunities and space for regulators......

Concern five:

While strengthening supervision, pharmaceutical companies are the main body of responsibility. Pharmaceutical companies need to be more strictly supervised, and they also need better "government" services and "policy" support, we need a more honest social environment and reasonable upstream and downstream interest relationship... We need drug production, drug circulation, medical insurance... All-round reform and improvement... If the board only hits the pharmaceutical people and the pressure only adds to the pharmaceutical industry... While other fields continue to go their own way, the pharmaceutical industry is bound to remain a "high-risk" industry......

This article is a few words, only on behalf of personal views, of course, we do not have to be too pessimistic about the pharmaceutical industry, the wheel of the times rolling forward, history, always want to turn a new page, we believe that the new drug supervision team will work harder to move forward, after the wind and rain, will certainly meet the rainbow!